CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals
This article was originally published in The Tan Sheet
FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.
You may also be interested in...
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
Sens. Hatch and Harkin ask FDA to craft a new document to replace the current NDI notification draft guidance, recommending the agency “provide needed clarification” on what constitutes an NDI.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.